Tidal Investments LLC grew its holdings in shares of Cencora, Inc. (NYSE:COR - Free Report) by 18.2% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 20,684 shares of the company's stock after buying an additional 3,189 shares during the quarter. Tidal Investments LLC's holdings in Cencora were worth $4,656,000 as of its most recent SEC filing.
Other hedge funds have also made changes to their positions in the company. New Millennium Group LLC bought a new position in Cencora during the 2nd quarter valued at $26,000. MFA Wealth Advisors LLC acquired a new stake in shares of Cencora in the 2nd quarter valued at about $30,000. Concord Wealth Partners bought a new position in shares of Cencora during the third quarter worth about $30,000. SYSTM Wealth Solutions LLC acquired a new position in Cencora in the second quarter worth about $36,000. Finally, Ashton Thomas Securities LLC bought a new stake in Cencora in the third quarter valued at about $41,000. Institutional investors and hedge funds own 97.52% of the company's stock.
In other news, Chairman Steven H. Collis sold 50,000 shares of the company's stock in a transaction that occurred on Monday, November 25th. The shares were sold at an average price of $243.97, for a total value of $12,198,500.00. Following the completion of the sale, the chairman now directly owns 326,557 shares of the company's stock, valued at approximately $79,670,111.29. This represents a 13.28 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Over the last quarter, insiders sold 93,018 shares of company stock valued at $22,478,942. 15.80% of the stock is currently owned by corporate insiders.
A number of research analysts have commented on COR shares. Mizuho initiated coverage on Cencora in a report on Wednesday, December 4th. They set an "outperform" rating and a $280.00 target price on the stock. Wells Fargo & Company decreased their price objective on shares of Cencora from $249.00 to $237.00 and set an "equal weight" rating for the company in a report on Friday. UBS Group boosted their target price on shares of Cencora from $275.00 to $285.00 and gave the company a "buy" rating in a research note on Thursday, November 7th. JPMorgan Chase & Co. raised their price target on shares of Cencora from $280.00 to $287.00 and gave the stock an "overweight" rating in a research report on Wednesday, August 21st. Finally, Evercore ISI increased their price objective on shares of Cencora from $250.00 to $285.00 and gave the stock an "outperform" rating in a research note on Thursday, November 7th. Two investment analysts have rated the stock with a hold rating and ten have given a buy rating to the company. According to data from MarketBeat, Cencora has an average rating of "Moderate Buy" and a consensus target price of $275.60.
Read Our Latest Stock Analysis on Cencora
Shares of NYSE:COR opened at $232.24 on Friday. Cencora, Inc. has a fifty-two week low of $195.83 and a fifty-two week high of $253.27. The company has a quick ratio of 0.53, a current ratio of 0.88 and a debt-to-equity ratio of 4.84. The company has a market cap of $44.89 billion, a PE ratio of 30.92, a P/E/G ratio of 1.54 and a beta of 0.45. The company's 50-day moving average price is $238.36 and its 200 day moving average price is $233.91.
The firm also recently declared a quarterly dividend, which was paid on Friday, November 29th. Shareholders of record on Friday, November 15th were given a dividend of $0.55 per share. This represents a $2.20 dividend on an annualized basis and a yield of 0.95%. The ex-dividend date of this dividend was Friday, November 15th. This is a positive change from Cencora's previous quarterly dividend of $0.51. Cencora's payout ratio is 29.29%.
Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Before you consider Cencora, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cencora wasn't on the list.
While Cencora currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.